These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30781783)

  • 21. miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells.
    Nishijima N; Seike M; Soeno C; Chiba M; Miyanaga A; Noro R; Sugano T; Matsumoto M; Kubota K; Gemma A
    Int J Oncol; 2016 Mar; 48(3):937-44. PubMed ID: 26783187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TGF-β1-induced epithelial-mesenchymal transition in lung cancer cells involves upregulation of miR-9 and downregulation of its target, E-cadherin.
    Wang H; Wu Q; Zhang Y; Zhang HN; Wang YB; Wang W
    Cell Mol Biol Lett; 2017; 22():22. PubMed ID: 29118814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer.
    Ceppi P; Mudduluru G; Kumarswamy R; Rapa I; Scagliotti GV; Papotti M; Allgayer H
    Mol Cancer Res; 2010 Sep; 8(9):1207-16. PubMed ID: 20696752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
    He Y; Xie H; Yu P; Jiang S; Wei L
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
    Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Knockdown of LncRNA-XIST Suppresses Proliferation and TGF-β1-Induced EMT in NSCLC Through the Notch-1 Pathway by Regulation of miR-137.
    Wang X; Zhang G; Cheng Z; Dai L; Jia L; Jing X; Wang H; Zhang R; Liu M; Jiang T; Yang Y; Yang M
    Genet Test Mol Biomarkers; 2018 Jun; 22(6):333-342. PubMed ID: 29812958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Downregulation of miR-3127-5p promotes epithelial-mesenchymal transition via FZD4 regulation of Wnt/β-catenin signaling in non-small-cell lung cancer.
    Yang Y; Sun Y; Wu Y; Tang D; Ding X; Xu W; Su B; Gao W
    Mol Carcinog; 2018 Jul; 57(7):842-853. PubMed ID: 29566281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-16 mimics inhibit TGF-β1-induced epithelial-to-mesenchymal transition via activation of autophagy in non-small cell lung carcinoma cells.
    Wang H; Zhang Y; Wu Q; Wang YB; Wang W
    Oncol Rep; 2018 Jan; 39(1):247-254. PubMed ID: 29138833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-105 promotes epithelial-mesenchymal transition of nonsmall lung cancer cells through upregulating Mcl-1.
    Jin X; Yu Y; Zou Q; Wang M; Cui Y; Xie J; Wang Z
    J Cell Biochem; 2019 Apr; 120(4):5880-5888. PubMed ID: 30317672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RP11-874 J12.4 promotes erlotinib resistance in non-small cell lung cancer via increasing AXL expression.
    Huang S; Zhang J; Wu X; Liang B; Pang N; Yang L; Zhang Z
    Life Sci; 2024 Aug; 351():122849. PubMed ID: 38897346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COX-2 potentiates cisplatin resistance of non-small cell lung cancer cells by promoting EMT in an AKT signaling pathway-dependent manner.
    Jiang GB; Fang HY; Tao DY; Chen XP; Cao FL
    Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3838-3846. PubMed ID: 31115011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GBP1 promotes erlotinib resistance via PGK1‑activated EMT signaling in non‑small cell lung cancer.
    Cheng L; Gou L; Wei T; Zhang J
    Int J Oncol; 2020 Sep; 57(3):858-870. PubMed ID: 32582960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance.
    Mutlu M; Raza U; Saatci Ö; Eyüpoğlu E; Yurdusev E; Şahin Ö
    J Mol Med (Berl); 2016 Jun; 94(6):629-44. PubMed ID: 27094812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roles of miR-200 family members in lung cancer: more than tumor suppressors.
    Liu C; Hu W; Li LL; Wang YX; Zhou Q; Zhang F; Song-Yang YY; Zhu W; Sun CC; Li DJ
    Future Oncol; 2018 Nov; 14(27):2875-2886. PubMed ID: 30208739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conditioned medium of primary lung cancer cells induces EMT in A549 lung cancer cell line by TGF-ß1 and miRNA21 cooperation.
    Camerlingo R; Miceli R; Marra L; Rea G; D'Agnano I; Nardella M; Montella R; Morabito A; Normanno N; Tirino V; Rocco G
    PLoS One; 2019; 14(7):e0219597. PubMed ID: 31344049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells.
    Sesumi Y; Suda K; Mizuuchi H; Kobayashi Y; Sato K; Chiba M; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
    Lung Cancer; 2017 Feb; 104():85-90. PubMed ID: 28213007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PARP-1 induces EMT in non-small cell lung carcinoma cells via modulating the transcription factors Smad4, p65 and ZEB1.
    Kumar M; Jaiswal RK; Prasad R; Yadav SS; Kumar A; Yadava PK; Singh RP
    Life Sci; 2021 Mar; 269():118994. PubMed ID: 33417952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiRNA-200b represses transforming growth factor-β1-induced EMT and fibronectin expression in kidney proximal tubular cells.
    Tang O; Chen XM; Shen S; Hahn M; Pollock CA
    Am J Physiol Renal Physiol; 2013 May; 304(10):F1266-73. PubMed ID: 23408168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC.
    Iderzorig T; Kellen J; Osude C; Singh S; Woodman JA; Garcia C; Puri N
    Biochem Biophys Res Commun; 2018 Feb; 496(2):770-777. PubMed ID: 29337056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncogenic miR-9 is a target of erlotinib in NSCLCs.
    Chen X; Zhu L; Ma Z; Sun G; Luo X; Li M; Zhai S; Li P; Wang X
    Sci Rep; 2015 Nov; 5():17031. PubMed ID: 26593208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.